EA199800208A1 - Усовершенствованные способы изготовления нековалентно комплексированных и поливалентных вакцин протеосомной подгруппы - Google Patents

Усовершенствованные способы изготовления нековалентно комплексированных и поливалентных вакцин протеосомной подгруппы

Info

Publication number
EA199800208A1
EA199800208A1 EA199800208A EA199800208A EA199800208A1 EA 199800208 A1 EA199800208 A1 EA 199800208A1 EA 199800208 A EA199800208 A EA 199800208A EA 199800208 A EA199800208 A EA 199800208A EA 199800208 A1 EA199800208 A1 EA 199800208A1
Authority
EA
Eurasian Patent Office
Prior art keywords
ultrafiltration
production
amphiphilic
diafiltration
proteasome
Prior art date
Application number
EA199800208A
Other languages
English (en)
Inventor
Джордж Х. Лоувелл
Венделл Д. Золлингер
Джеймс Ф. Вудс
Original Assignee
Юнайтед Стэйтс Арми Медикал Ресерч Материэл Комманд (Юсамрмк)
Джордж Х. Лоувелл
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21707938&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA199800208(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Юнайтед Стэйтс Арми Медикал Ресерч Материэл Комманд (Юсамрмк), Джордж Х. Лоувелл filed Critical Юнайтед Стэйтс Арми Медикал Ресерч Материэл Комманд (Юсамрмк)
Publication of EA199800208A1 publication Critical patent/EA199800208A1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/385Haptens or antigens, bound to carriers
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23JPROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
    • A23J1/00Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
    • A23J1/008Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from microorganisms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1275Lipoproteins; Chylomicrons; Artificial HDL, LDL, VLDL, protein-free species thereof; Precursors thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/25Shigella (G)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Communicable Diseases (AREA)
  • Food Science & Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Способ изготовления поливалентных вакцин с протеосом-амфифильной детерминантой, пригодных для применения парентерально или через слизистую оболочку, с использованием диафильтрационной или ультрафильтрационной технологии. Амфифильные детерминанты включают липополисахариды грамотрицательных бактерий, например S.flexneri, P.shigelloides и S.sonnei. Протеосомы получены из менингококков группы В типа 2b. Активные вакцинные комплексы (нековалентные комплексы) с протеосом-амфифильной детерминантой изготовлены с использованием диафильтрации или ультрафильтрации для удаления детергента. Применение диа- или ультрафильтрации сокращает время переработки и уменьшает возможность загрязнения, а также позволяет осуществлять процесс при комнатной температуре и эффективно повышать масштабы производства. К тому же способ дает возможность надежно и непрерывно контролировать диализат, что повышает эффективность процесса в целом. Время диализа при изготовлении вакцинной серии сокращено с 7-10 суток до 72 ч и менее, а на практике - менее чем до 48 или 24 ч. Использование способа позволяет оптимизировать содержание каждого антигенного компонента в препаратах поливалентных вакцин.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA199800208A 1995-09-18 1996-09-18 Усовершенствованные способы изготовления нековалентно комплексированных и поливалентных вакцин протеосомной подгруппы EA199800208A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US385995P 1995-09-18 1995-09-18
PCT/US1996/015002 WO1997010844A1 (en) 1995-09-18 1996-09-18 Improved methods for the production of non-covalently complexed and multivalent proteosome sub-unit vaccines

Publications (1)

Publication Number Publication Date
EA199800208A1 true EA199800208A1 (ru) 1998-10-29

Family

ID=21707938

Family Applications (1)

Application Number Title Priority Date Filing Date
EA199800208A EA199800208A1 (ru) 1995-09-18 1996-09-18 Усовершенствованные способы изготовления нековалентно комплексированных и поливалентных вакцин протеосомной подгруппы

Country Status (20)

Country Link
US (1) US6476201B1 (ru)
EP (1) EP0854729B2 (ru)
JP (2) JP4033489B2 (ru)
KR (1) KR19990045763A (ru)
CN (1) CN1211192A (ru)
AT (1) ATE261313T1 (ru)
BR (1) BR9610484A (ru)
CA (1) CA2232410C (ru)
CZ (1) CZ298460B6 (ru)
DE (1) DE69631835T3 (ru)
DK (1) DK0854729T3 (ru)
EA (1) EA199800208A1 (ru)
ES (1) ES2217325T5 (ru)
HU (1) HUP9901577A3 (ru)
IL (1) IL123720A (ru)
MX (1) MX9802128A (ru)
NO (1) NO320074B1 (ru)
PL (1) PL325604A1 (ru)
PT (1) PT854729E (ru)
WO (1) WO1997010844A1 (ru)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5961970A (en) * 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
CA2332963C (en) * 1998-05-29 2013-07-23 Chiron Corporation Combination meningitidis b/c vaccines
NZ581940A (en) 1999-04-30 2011-07-29 Novartis Vaccines & Diagnostic Conserved neisserial antigens
EP1179072A2 (en) * 1999-05-19 2002-02-13 Chiron S.P.A. Combination neisserial compositions
EP1721618A3 (en) * 2000-02-15 2007-01-10 ID Biomedical Corporation of Quebec Proteosome influenza vaccine composition
EP1255561B1 (en) * 2000-02-15 2006-06-28 ID Biomedical Corporation of Quebec Proteosome influenza vaccine
PT1947187E (pt) 2000-02-28 2011-07-04 Novartis Vaccines & Diagnostic Expressões híbridas de proteínas de neisseria
WO2002072012A2 (en) * 2001-03-09 2002-09-19 Id Biomedical Corporation Of Quebec A novel proteosome-liposaccharide vaccine adjuvant
JP2006506467A (ja) * 2002-08-02 2006-02-23 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン組成物
SI2351579T1 (sl) 2002-10-11 2017-05-31 Glaxosmithkline Biologicals Sa Polipeptidna cepiva za široko zaščito proti hipervirulentnim meningokoknim linijam
US7255867B2 (en) * 2002-11-15 2007-08-14 Id Biomedical Corporation Of Quebec Vaccine
GB0316560D0 (en) * 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
US7368537B2 (en) * 2003-07-15 2008-05-06 Id Biomedical Corporation Of Quebec Subunit vaccine against respiratory syncytial virus infection
JP2007505836A (ja) * 2003-09-15 2007-03-15 アイディー バイオメディカル コーポレイション オブ ケベック 麻疹サブユニットワクチン
US8173140B2 (en) 2003-10-22 2012-05-08 Id Biomedical Corporation Of Quebec Compositions and methods for activating innate and allergic immunity
CN101039691B (zh) 2004-06-25 2013-07-31 魁北克益得生物医学公司 用于治疗神经疾病的组合物和方法
RU2007103343A (ru) * 2004-06-30 2008-08-10 АйДи БАЙОМЕДИКАЛ КОРПОРЕЙШН ОФ КВЕБЕК (CA) Вакцинная композиция и способы лечения коронавирусной инфекции
US7552948B2 (en) 2006-03-29 2009-06-30 Tokai Rubber Industries, Ltd. Quick connector
ZA200900899B (en) * 2006-08-07 2010-07-28 Harvard College Protein matrix vaccines and methods of making and administering such vaccines
TWI565713B (zh) 2006-08-07 2017-01-11 哈佛大學校長及研究員協會 蛋白基質疫苗以及該疫苗的製造與使用方法
US20100288029A1 (en) * 2006-08-30 2010-11-18 Ge Healthcar Bio-Sciences Corp. System and method for characterizing membranes and membrane filtration devices
RU2477145C2 (ru) * 2008-05-30 2013-03-10 ДЗЕ Ю.Эс.Эй., ЭС РЕПРЕЗЕНТЕД БАЙ ДЗЕ СЕКРЕТАРИ ОФ ДЗЕ АРМИ, ОН БЕХАФ ОФ УОЛТЕР РИД АРМИ Мультивалентная вакцина из нативных везикул наружной мембраны менингококков, способы ее получения и применения
US20120231086A1 (en) * 2009-09-09 2012-09-13 Killen Kevin P Protein matrix vaccines of improved immunogenicity
AU2015321698B2 (en) * 2014-09-24 2018-06-28 The United States Of America As Represented By The Secretary Of The Navy Combined enterotoxigenic Escherichia coli and Campylobacter jejuni recombinant construct
US20220226465A1 (en) 2021-01-18 2022-07-21 ConserV Bioscience Coronavirus Immunogenic Compositions, Methods and Uses Thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4707543A (en) * 1985-09-17 1987-11-17 The United States Of America As Represented By The Secretary Of The Army Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines
RU1522494C (ru) * 1987-06-16 1994-11-15 Научно-производственное объединение "Иммунопрепарат" Способ получения инактивированной вакцины гриппа
RU2023448C1 (ru) * 1987-07-30 1994-11-30 Сентро Насьональ Де Биопрепарадос Способ получения вакцины против различных патогенных серотипов менингита нейссера группы в
US5145702A (en) * 1988-09-19 1992-09-08 Opta Food Ingredients, Inc. Hydrophobic protein microparticles and preparation thereof
EP0449958B9 (en) * 1988-12-19 2003-05-28 American Cyanamid Company Meningococcal class 1 outer-membrane protein vaccine
US5102989A (en) * 1991-03-15 1992-04-07 Merck & Co., Inc. Method of stabilizing recombinant hepatitis B virus surface proteins from recombinant host cells
WO1994002626A1 (en) * 1992-07-20 1994-02-03 Merck & Co., Inc. Immunological conjugates of ompc and hiv-specific selected principal neutralization epitopes
US5576016A (en) * 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
WO1995011700A1 (en) * 1993-10-29 1995-05-04 Pharmos Corp. Submicron emulsions as vaccine adjuvants
EP1255561B1 (en) * 2000-02-15 2006-06-28 ID Biomedical Corporation of Quebec Proteosome influenza vaccine

Also Published As

Publication number Publication date
KR19990045763A (ko) 1999-06-25
EP0854729A4 (en) 2000-02-02
ES2217325T3 (es) 2004-11-01
JP4033489B2 (ja) 2008-01-16
ATE261313T1 (de) 2004-03-15
US20020164357A1 (en) 2002-11-07
IL123720A (en) 2002-02-10
PL325604A1 (en) 1998-08-03
CZ81998A3 (cs) 1998-10-14
US6476201B1 (en) 2002-11-05
NO320074B1 (no) 2005-10-17
DK0854729T3 (da) 2004-07-12
IL123720A0 (en) 1998-10-30
EP0854729B2 (en) 2008-10-22
NO981189D0 (no) 1998-03-17
DE69631835T3 (de) 2009-03-05
CN1211192A (zh) 1999-03-17
PT854729E (pt) 2004-08-31
BR9610484A (pt) 2001-09-11
CA2232410C (en) 2003-06-17
ES2217325T5 (es) 2009-04-01
MX9802128A (es) 1998-11-29
EP0854729B1 (en) 2004-03-10
CZ298460B6 (cs) 2007-10-10
JP2000507913A (ja) 2000-06-27
DE69631835T2 (de) 2005-02-10
HUP9901577A2 (hu) 1999-08-30
HUP9901577A3 (en) 2000-03-28
JP2004099619A (ja) 2004-04-02
EP0854729A1 (en) 1998-07-29
WO1997010844A1 (en) 1997-03-27
DE69631835D1 (de) 2004-04-15
NO981189L (no) 1998-05-14
CA2232410A1 (en) 1997-03-27

Similar Documents

Publication Publication Date Title
EA199800208A1 (ru) Усовершенствованные способы изготовления нековалентно комплексированных и поливалентных вакцин протеосомной подгруппы
NO913518L (no) Vaksiner for ikke typebestembar haemophilus influenzae.
Verstreate et al. Outer membrane proteins of Brucella abortus: isolation and characterization
CA1146862A (en) Multivalent pneumococcal vaccine and preparation thereof
HRP20170845T1 (hr) Hiperbulirajući sojevi bakterije shigella
Ortiz et al. Immunoblot detection of class-specific humoral immune response to outer membrane proteins isolated from Salmonella typhi in humans with typhoid fever
CA2277141A1 (en) Process for preparing conjugate vaccines including free protein and the conjugate vaccines, immunogens, and immunogenic reagents produced by this procedure
SE9003278D0 (sv) Foerfarande respektive anlaeggning foer beredning av en medicinsk loesning, t ex en dialysloesning
EA010057B1 (ru) Инактивированная полиомиелитная вакцина, полученная из штамма сейбина вируса полиомиелита
JP4874339B2 (ja) Ipv−dptワクチン
EP0082072B1 (fr) Procédé de production d'un vaccin biochimique contre les fièvres à salmonelles
US3769415A (en) Method of preparing a killed vaccine for oral use
EP0090660A3 (en) Neisseria gonorrhoeae vaccine
NO124840B (ru)
Al-Harbi et al. The immune response of turbot, Scophthalmus maximus (L.), to lipopolysaccharide from a fish-pathogenic Cytophaga-like bacterium.
US6413515B1 (en) Avian, vitelline antibodies directed against HIV antigens
RU2283135C1 (ru) Способ выделения очищенных полисахаридов менингококков серогрупп а и с
CA1206879A (en) Method of obtaining of interferon and interferon in complex with antibacterial and antitoxic substances
ATE101521T1 (de) Ein reines faktor i-protein und verfahren zur herstellung.
SU1725904A1 (ru) Способ получени бруцеллезной вакцины из штамма 82
JPS584729A (ja) 人の血漿からの純粋肝炎b表面抗原の製造法
JPH0689025B2 (ja) 卵黄からの水溶性タンパク質の回収方法
CN116041560A (zh) 一种规模化制备类志贺邻单胞菌特异性多糖的方法
Cohen et al. FOR THE| N| VITRO CULTIVATION OF TRYPANOSOMA CRUZI
Beynon A structural investigation of the capsular antigens of two Escherichia coli strains K26 and K49.